INTRODUCTION
============

Although the etiology of many diseases is not completely understood, most are likely to be caused by interactions between hazardous environmental factors and the host genome. Recent advances in genotyping techniques have allowed many epidemiologic studies to investigate gene--environment interactions in chronic diseases.^[@r01]--[@r04]^ Cohort and case--control studies focusing on such interactions are ongoing worldwide, and these investigations use DNA from established and new cohorts.^[@r05]--[@r08]^ Understanding gene--environment interactions requires long-term cohort studies to clarify the temporality of associations and to avoid information and selection biases that are inevitable in cross-sectional and case--control studies.^[@r09]^ For most multifactorial diseases, such cohort studies must be conducted on a large scale to ensure significant results.

The Japan Multi-institutional Collaborative Cohort (J-MICC) Study is a new cohort study that was launched in 2005 to examine gene--environment interactions in lifestyle-related diseases, especially cancers. It is supported by a research grant for Scientific Research on Special Priority Areas of Cancer from the Japanese Ministry of Education, Culture, Sports, Science and Technology (MEXT).^[@r10],[@r11]^ The J-MICC Study group is composed of 10 cohorts surveyed by 10 independent research teams.^[@r12],[@r13]^

Although the long-term aim of this study is to elucidate gene--environment interactions in the whole cohort, some of its research objectives will be achieved by cross-sectional studies. In 2009, we started a cross-sectional study to examine correlations between lifestyle and medical factors, as assessed using questionnaires and medical examinations, and the distribution of possible related genotypes. Here we describe the recruitment and profile of the participants, including their genotype analysis, and selected demographic, lifestyle, and medical characteristics.

METHODS
=======

Study participants, data collection, and blood sampling
-------------------------------------------------------

The participants in this study completed questionnaires on lifestyle factors and diseases and donated blood samples at the time of the baseline survey for the J-MICC Study. The details of the J-MICC Study have been described elsewhere.^[@r10]^ The participants were enrolled in 9 study areas throughout Japan between 2005 and 2008, and in 1 area in 2004, under the supervision of an associate member of the J-MICC Study. The study participants were enrolled from the community by mailing invitation letters or distributing leaflets (3 areas), or by recruiting patients at their first visit to a cancer hospital (1 area) or at health checkups (6 areas). The response rates for the baseline survey were 7.0%, 36.5%, 25.9%, 58.4%, 60.1%, 37.6%, 14.0%, 24.0%, 19.7%, and 65.5% for the Chiba, Shizuoka, Okazaki, Aichi Cancer Center, Takashima, Kyoto, Tokushima, Fukuoka, Saga, and Amami areas, respectively. For cases in which the baseline survey is still ongoing in a cohort, the latest response rate (as of 30 September 2010 or later) was used. Anthropometry, blood pressure, and blood chemistry data obtained from health checkups were available in 8 of the study areas. The subjects for the cross-sectional study comprised 500 to 600 participants enrolled consecutively in each area of the J-MICC Study, except in 2 areas, where fewer participants had been recruited. The recruitment period for the present study, however, was arbitrarily defined by the researchers in each area after the enrollment.

Of the 5108 men and women initially selected, we excluded participants for whom we did not have sufficient DNA (*n* = 442), appropriate informed consent (*n* = 8), questionnaire data (*n* = 9), or local government registration of residence in the study area (*n* = 7), as well as anyone who had declined follow up (*n* = 2) or withdrew from the study (*n* = 1), and the 120 participants who were younger than 35 years or older than 69 years. Thus, our final study group comprised 4519 participants aged 35 to 69 years.

All the participants included in this analysis had provided written informed consent. The ethics committees of Nagoya University School of Medicine (the affiliation of the former principal investigator, Nobuyuki Hamajima) and the other participating institutions approved the protocol for the J-MICC Study.

Genotyping
----------

We chose 107 single nucleotide polymorphisms (SNPs) and 1 insertion/deletion polymorphism for genotyping, based on their potential relevance to the lifestyle and medical factors described in the next section ("Lifestyle and clinical data"). Researchers from all participating cohorts proposed potentially relevant polymorphisms, and those selected for inclusion in the present study were determined through discussion among the members of the J-MICC Study Group.

In all study areas except Fukuoka, buffy coat fractions were prepared from blood samples and stored at −80°C at the central J-MICC Study office. DNA was extracted from all buffy coat fractions using a BioRobot M48 Workstation (Qiagen Group, Tokyo, Japan) at the central study office. For the samples from the Fukuoka area, DNA was extracted locally from samples of whole blood, using an automatic nucleic acid isolation system (NA-3000, Kurabo, Co., Ltd, Osaka, Japan). The buffy coat fractions or DNA samples were anonymized in a linkable manner^[@r14]^ and then sent to the central office.

The selected polymorphisms were genotyped using the multiplex polymerase chain reaction (PCR)-based Invader assay^[@r15]^ (Third Wave Technologies, Madison, WI, USA) at the Laboratory for Genotyping Development, Center for Genomic Medicine, RIKEN.

Lifestyle and clinical characteristics
--------------------------------------

The lifestyle factors considered were smoking and drinking habits, coffee consumption, sleep, and mental stress, while the clinical characteristics were height, weight, blood pressure, blood glucose, glycated hemoglobin (HbA1c), serum triglyceride, total and high-density lipoprotein (HDL) cholesterol, uric acid, aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyltransferase (γ-GT), C-reactive protein (CRP), creatinine, and bone mineral density. Ages at menarche and menopause were also ascertained.

We used a standard questionnaire in all study areas except the Fukuoka area, where some questions are slightly different from those of other areas. Furthermore, a validated food-frequency questionnaire was used for the dietary assessment.^[@r16]--[@r19]^ We were unable to directly control the quality of information from health examinations because most data were obtained at routine health checkups offered by other institutions. However, the J-MICC Study Group is now collecting information on participation in the Japan Medical Association's quality control program for clinical laboratories and the instruction manuals used for measurement of blood pressure, height, and weight. For the current report, participants whose blood was drawn less than 3 hours after their last meal were excluded from the analysis of serum lipids and blood glucose.

Statistical analysis
--------------------

We tabulated selected baseline characteristics by sex and 10-year age group or by sex and study area. In this analysis, body mass index (BMI; kg/m^2^) was calculated on the basis of self-reported height and body weight, as independent measurements were not available in some study areas. In the case of educational attainment, participants from the Fukuoka area were excluded from the analysis because the questionnaire used there had not included this item. Participants who consumed alcohol at least once a week were classified as drinkers. To compare characteristics among participating cohorts, we attempted to adjust for age by using the direct method (for proportions) or the general linear model (for means). The variations among study areas, however, were not significantly altered after adjusting for age. Thus, in this report, we present only crude figures by sex and study area. The difference in the minor allele frequency (MAF) among the cohorts was tested by the chi-square test for contingency tables. The MAF of the *ABCC11* Arg180Gly (T/C) polymorphism by study area is not presented here because the inter-area variation in the distribution of this genotype will be reported in a separate article.

Genotypes with distributions that departed from the Hardy--Weinberg equilibrium were assessed using the exact test^[@r20]^ with the genhwi command of Stata version 8.0 (Stata Corp, College Station, TX, USA). Other statistical analyses were performed using Statistical Analysis System version 9.1 (SAS Institute Inc, Cary, NC, USA).^[@r21]^ To compare the allele frequencies of genotypes in our study with those in another Japanese population, we used data from HapMap, which is an open access database that includes allele frequencies for 45 Japanese in Tokyo (HapMap-JPT, <http://www.ncbi.nlm.nih.gov/snp>). Of the 108 polymorphisms of interest, we made comparisons for 88. The 20 polymorphisms excluded from our analysis showed no minor alleles in our study group (*n* = 4), were not represented (*n* = 15), or had invalid data (*n* = 1, 100% heterozygotes) in the HapMap-JPT data set.

RESULTS
=======

Our analysis included 2124 men (47.0%) and 2395 women (53.0%) with a mean age ± standard deviation at baseline of 55.8 ± 8.9 years (range, 35--69 years). There were considerable differences in the age and sex distributions of different study areas (Table [1](#tbl01){ref-type="table"}). In Fukuoka and Saga, the participants originally enrolled in the J-MICC Study were limited to adults aged 50 years or older and 40 years or older, respectively.

###### Sex and age distribution of study participants by study area

  Study area            Men   Women                                                                                                                    
  --------------------- ----- ------- ----- ------ ----- ------ ----- ------ ------ ------- ----- ------ ----- ------ ----- ------ ----- ------ ------ -------
  Chiba                 4     2.7     22    14.8   56    37.6   67    45.0   149    100.0   30    8.4    138   38.7   118   33.1   71    19.9   357    100.0
  Shizuoka              21    5.0     122   29.3   175   42.1   98    23.6   416    100.0   16    10.1   35    22.0   70    44.0   38    23.9   159    100.0
  Okazaki               13    4.8     29    10.6   66    24.2   165   60.4   273    100.0   12    4.7    45    17.6   85    33.3   113   44.3   255    100.0
  Aichi Cancer Center   12    4.4     32    11.6   115   41.8   116   42.2   275    100.0   33    10.9   88    29.0   102   33.7   80    26.4   303    100.0
  Takashima             7     4.2     18    10.7   45    26.8   98    58.3   168    100.0   27    7.2    59    15.8   102   27.3   186   49.7   374    100.0
  Kyoto                 37    30.3    31    25.4   48    39.3   6     4.9    122    100.0   9     23.7   19    50.0   9     23.7   1     2.6    38     100.0
  Tokushima             8     11.0    21    28.8   24    32.9   20    27.4   73     100.0   1     4.5    9     40.9   10    45.5   2     9.1    22     100.0
  Fukuoka               0     0.0     0     0.0    60    31.9   128   68.1   188    100.0   0     0.0    0     0.0    96    37.5   160   62.5   256    100.0
  Saga                  0     0.0     31    12.7   82    33.5   132   53.9   245    100.0   0     0.0    64    19.3   127   38.4   140   42.3   331    100.0
  Amami                 1     0.5     53    24.7   82    38.1   79    36.7   215    100.0   1     0.3    77    25.7   135   45.0   87    29.0   300    100.0
                                                                                                                                                       
  Total                 103   4.8     359   16.9   753   35.5   909   42.8   2124   100.0   129   5.4    534   22.3   854   35.7   878   36.7   2395   100.0

Table [2](#tbl02){ref-type="table"} summarizes selected demographic, lifestyle, and medical characteristics of the participants by sex and age. Within our sample, 29.1% of men and 7.1% of women were current smokers. More than two thirds (71.4%) of men drank alcoholic beverages at least once a week, as did 27.7% of the women. Table [3](#tbl03){ref-type="table"} presents data on selected lifestyle and medical variables of the participants by sex and study area. Considerable variations were found among the participating cohorts.

###### Selected demographic, lifestyle, and medical characteristics of participants by sex and age

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                          Men            Women                                                                                                                   
  --------------------------------------- -------------- -------------- -------------- -------------- -------------- -------------- -------------- -------------- -------------- --------------
  *n*                                     103            359            753            909            2124           129            534            854            878            2395

  Educational attainment (%)^a^                                                                                                                                                  

   Elementary/junior\                     1.0            3.1            10.0           20.9           12.6           2.3            2.1            9.8            31.6           14.7
  ​ high school                                                                                                                                                                  

   High school                            42.7           37.8           41.9           43.7           41.9           41.9           38.4           50.7           46.4           45.6

   Vocational school                      14.6           9.5            6.8            3.2            6.3            15.5           13.9           12.7           10.6           12.5

   Junior college                         3.9            4.8            3.9            2.2            3.4            24.8           26.5           16.1           7.4            16.3

   University                             33.0           39.5           34.8           27.6           32.7           15.5           17.7           10.2           3.8            10.2

   Postgraduate school                    4.9            5.0            2.2            1.7            2.6            0.0            1.5            0.5            0.0            0.6

   Others                                 0.0            0.3            0.4            0.7            0.5            0.0            0.0            0.0            0.1            0.0

  Current smokers (%)                     39.8           32.3           34.8           21.9           29.1           11.6           10.3           7.4            4.1            7.1

  Ex-smokers (%)                          25.2           35.7           41.8           48.6           42.9           5.4            7.9            4.8            2.8            4.8

  Current drinkers (%)^b^                 60.2           70.8           75.1           69.9           71.4           32.6           34.6           27.5           22.8           27.7

  Exercise ≥1/month (%)                   75.7           81.6           79.7           86.8           82.9           62.0           70.4           74.9           82.5           76.0

  Body mass\                              37.9           32.2           32.6           24.9           29.5           9.5            16.5           20.0           21.8           19.3
  ​index ≥25.0 (%)                                                                                                                                                               

  History of disease (%)                                                                                                                                                          

   Diabetes                               1.9            4.5            8.4            13.9           9.7            0.0            0.6            3.4            7.1            3.8

   Hypertension                           3.9            8.9            23.2           36.2           25.2           0.0            4.3            17.1           30.5           17.9

   Coronary heart\                        0.0            1.1            2.1            7.3            4.0            0.8            0.6            2.8            5.3            3.0
  ​ disease                                                                                                                                                                      

   Stroke                                 0.0            1.1            2.7            3.9            2.8            2.3            0.9            1.6            2.9            2.0

   Cancer                                 6.1            2.0            7.7            12.6           8.6            2.8            5.0            9.3            6.4            6.9

  Blood pressure and blood chemistry^c^                                                                                                                                          

   Systolic blood\                        120.4 ± 14.3   121.1 ± 15.4   129.7 ± 17.9   135.4 ± 19.3   130.1 ± 18.8   109.6 ± 11.4   116.8 ± 18.3   125.0 ± 18.9   133.4 ± 19.0   126.5 ± 19.9
  ​ pressure (mm Hg)                                                                                                                                                             

   Diastolic blood\                       73.6 ± 10.3    77.6 ± 11.7    81.9 ± 12.6    82.1 ± 11.1    80.8 ± 11.9    65.4 ± 7.4     72.0 ± 11.9    76.7 ± 11.6    79.0 ± 10.8    76.4 ± 11.7
  ​ pressure (mm Hg)                                                                                                                                                             

   Total cholesterol\                     191.3 ± 28.9   205.3 ± 30.2   206.6 ± 32.5   205.2 ± 33.1   205.2 ± 32.3   185.6 ± 25.2   202.4 ± 31.0   223.3 ± 34.2   223.1 ± 33.5   217.9 ± 34.6
  ​ (mg/dl)                                                                                                                                                                      

   HDL-cholesterol\                       56.2 ± 16.0    57.6 ± 15.4    59.1 ± 15.8    59.7 ± 16.2    58.9 ± 15.9    73.1 ± 15.7    68.7 ± 15.3    68.9 ± 15.0    66.2 ± 16.0    68.0 ± 15.5
  ​ (mg/dl)                                                                                                                                                                      

   Triglyceride (mg/dl)                   128.6 ± 74.9   146.5 ± 96.5   135.1 ± 93.0   132.0 ± 92.9   135.9 ± 93.0   64.8 ± 28.4    88.0 ± 61.2    104.9 ± 64.2   113.7 ± 69.2   103.4 ± 65.7

   Blood glucose (mg/dl)                  98.0 ± 27.2    98.3 ± 15.7    103.2 ± 17.6   103.9 ± 23.3   102.1 ± 20.3   86.8 ± 7.1     92.4 ± 19.7    95.9 ± 16.8    97.1 ± 15.8    95.1 ± 16.9

   HbA1c (%)                              4.96 ± 0.32    5.12 ± 0.48    5.32 ± 0.86    5.30 ± 0.75    5.27 ± 0.74    4.86 ± 0.27    4.96 ± 0.36    5.17 ± 0.64    5.26 ± 0.57    5.17 ± 0.57
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Plus-minus values are means ± SDs.

^a^Participants in Fukuoka area were excluded from the analysis because they were not asked about educational attainment in the questionnaire.

^b^Individuals who drank alcoholic beverages ≥1 day/week.

^c^Not available in some study areas, as shown in Table [3](#tbl03){ref-type="table"}.

###### Selected lifestyle and medical characteristics of participants by sex and study area

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                     *n*    Study area                                                                                                                             
  ---------------------------------- ------ -------------- ------ -------------- -------------- ------ -------------- -------------- -------------- --------------- -------------- ---------------
  Men                                                                                                                                                                               

   Current smokers (%)               2123   29.1           23.5   23.6           25.6           31.0   35.7           41.8           31.5           33.0            34.3           23.3

   Ex-smokers (%)                    2123   42.9           42.3   48.3           50.2           44.2   33.3           33.6           38.4           39.4            42.9           39.1

   Current drinkers (%)^a^           2121   71.4           78.5   73.4           62.6           66.9   73.8           68.0           61.6           70.2            71.4           84.1

   Exercise ≥1/month (%)             2109   82.9           87.1   88.7           81.0           83.5   60.1           81.0           94.5           89.9            85.3           75.9

   Body mass index ≥25.0 (%)         2114   29.5           29.1   25.2           26.4           22.6   27.0           23.8           41.1           31.4            27.7           52.8

   History of hypertension (%)       2052   25.2           28.2   14.7           29.5           24.0   28.7           9.9            21.9           44.4            28.6           32.1

                                                                                                                                                                                   

   Systolic blood pressure (mm Hg)   1698   130.1 ± 18.8   NA     121.9 ± 14.8   128.7 ± 15.2   NA     133.0 ± 19.5   122.8 ± 16.0   119.8 ± 17.6   144.0 ± 19.6    138.3 ± 19.3   132.0 ± 17.7

   Diastolic blood pressure\         1698   80.8 ± 11.9    NA     76.5 ± 10.5    81.4 ± 9.1     NA     81.2 ± 11.2    74.3 ± 11.9    73.7 ± 12.8    88.0 ± 11.1     86.0 ± 12.8    81.9 ± 11.1
  ​ (mm Hg)                                                                                                                                                                        

   Total cholesterol (mg/dl)         1296   205.2 ± 32.3   NA     201.3 ± 29.3   205.9 ± 32.0   NA     208.3 ± 35.6   ---^b^         209.0 ± 31.4   209.9 ± 31.5    203.6 ± 33.6   208.0 ± 35.7

   HDL-cholesterol (mg/dl)           1378   58.9 ± 15.9    NA     58.3 ± 15.4    64.1 ± 17.5    NA     59.4 ± 17.0    61.4 ± 17.6    52.5 ± 11.6    54.5 ± 16.1     55.3 ± 14.2    57.7 ± 13.4

   Triglyceride (mg/dl)              1377   135.9 ± 93.0   NA     122.8 ± 68.6   120.8 ± 86.5   NA     116.9 ± 60.0   127.9 ± 85.7   126.7 ± 64.2   181.5 ± 131.9   164.9 ± 93.6   165.7 ± 130.8

   Blood glucose (mg/dl)             1175   102.1 ± 20.3   NA     101.1 ± 14.3   100.0 ± 17.0   NA     97.9 ± 16.3    98.7 ± 25.0    104.2 ± 26.4   NA              NA             110.3 ± 28.8

   HbA1c (%)                         1354   5.27 ± 0.74    NA     5.27 ± 0.56    5.36 ± 0.64    NA     5.24 ± 0.79    NA             5.17 ± 0.52    5.17 ± 0.82     5.28 ± 1.04    5.31 ± 0.42

                                                                                                                                                                                   

  Women                                                                                                                                                                             

   Current smokers (%)               2390   7.1            7.6    5.0            6.3            12.4   5.6            15.8           0.0            9.0             5.4            4.4

   Ex-smokers (%)                    2390   4.8            6.7    4.4            5.9            8.4    1.3            7.9            4.6            4.7             5.7            1.0

   Current drinkers (%)^a^           2383   27.7           36.1   27.2           22.4           31.7   24.6           34.2           22.7           25.0            28.2           23.3

   Exercise ≥1/month (%)             2381   76.0           82.8   81.8           83.9           70.9   55.6           44.7           81.8           88.3            83.4           73.1

   Body mass index ≥25.0 (%)         2359   19.3           12.8   15.5           17.3           14.0   21.9           15.8           27.3           19.5            16.5           36.2

   History of hypertension (%)       2289   17.9           10.4   15.8           19.3           12.9   18.5           7.9            18.2           37.9            17.6           22.0

                                                                                                                                                                                   

   Systolic blood pressure (mm Hg)   1732   126.5 ± 19.9   NA     115.7 ± 16.8   122.7 ± 15.6   NA     124.6 ± 19.5   120.4 ± 19.5   111.5 ± 11.7   137.5 ± 21.9    129.5 ± 19.5   126.8 ± 19.0

   Diastolic blood pressure\         1732   76.4 ± 11.7    NA     70.3 ± 10.5    76.7 ± 9.5     NA     73.6 ± 11.4    71.8 ± 11.1    68.2 ± 10.3    84.0 ± 11.3     77.9 ± 12.2    76.0 ± 10.4
  ​ (mm Hg)                                                                                                                                                                        

   Total cholesterol (mg/dl)         1318   217.9 ± 34.6   NA     206.4 ± 31.9   213.5 ± 34.1   NA     222.6 ± 36.5   NA             210.0 ± 35.7   230.1 ± 31.4    220.3 ± 33.5   218.0 ± 33.7

   HDL-cholesterol (mg/dl)           1347   68.0 ± 15.5    NA     72.3 ± 16.1    75.0 ± 16.9    NA     67.0 ± 15.0    69.3 ± 13.7    65.5 ± 12.0    66.1 ± 16.6     64.3 ± 14.1    63.4 ± 12.6

   Triglyceride (mg/dl)              1347   103.4 ± 65.7   NA     80.0 ± 40.9    97.3 ± 60.9    NA     96.8 ± 54.9    68.6 ± 27.8    84.3 ± 41.2    128.0 ± 66.0    129.2 ± 83.4   109.4 ± 74.2

   Blood glucose (mg/dl)             1072   95.1 ± 16.9    NA     91.9 ± 8.3     94.7 ± 13.7    NA     91.0 ± 10.2    89.6 ± 7.1     101.9 ± 31.9   NA              NA             101.8 ± 24.3

   HbA1c (%)                         1396   5.17 ± 0.57    NA     5.15 ± 0.35    5.32 ± 0.57    NA     5.11 ± 0.54    NA             ---^b^         5.16 ± 0.65     5.10 ± 0.59    ---^b^
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: ACC, Aichi Cancer Center; HDL, high-density lipoprotein; NA, not available.

Plus-minus values are means ± SDs.

^a^Individuals who drank alcoholic beverages ≥1 day/week.

^b^Data available for fewer than 20 participants.

The genotype distributions and allele frequencies of the analyzed genetic polymorphisms are summarized in Table [4](#tbl04){ref-type="table"}. The call rate ranged from 99.40% to 99.98%. Of the 108 polymorphisms, the 4 SNPs for which we found no different alleles were *APOA1* Arg184Pro (G/C), *ESR1* IVS1-351A/G (*Xba* I), *LCAT/SLC12A4* Ser232Thr (T/A), and *SCARB1* Val135Ile (G/A). For the remaining 104 polymorphisms, the MAF varied from 0.016 (*PTGS2*(*COX2*) C-163G) to 0.492 (*CETP* Ile405Val (A/G)), and most of the variations were common (MAF ≥0.05 for 96 polymorphisms).

###### Genotype distributions and allele frequencies of 108 selected genetic polymorphisms (107 SNPs and 1 insertion/deletion polymorphism)

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gene             Polymorphism                   rs number    Genotype^a^   *n*^a^   Frequency (proportion)   *P* for\   MAF                                                                           
                                                                                                               HWE                                                                                      
  ---------------- ------------------------------ ------------ ------------- -------- ------------------------ ---------- ------ ------ ---- ------- ------- ------- ------- ------- ------- ---------- -------
  *ABCA1*          C-565T                         rs2422493    CC            CT       TT                       1634       2137   746    2    0.362   0.473   0.165   0.358   0.481   0.161   0.29       0.402

  *ABCA1*          G-191C                         rs1800976    GG            GC       CC                       1628       2144   746    1    0.360   0.475   0.165   0.357   0.481   0.162   0.37       0.402

  *ABCA1*          G-17C                          rs2740483    GG            GC       CC                       2211       1898   409    1    0.489   0.420   0.091   0.489   0.420   0.090   0.94       0.301

  *ABCA1*          Val825Ile (G/A)                rs2066715    GG            GA       AA                       1877       2064   577    1    0.415   0.457   0.128   0.415   0.459   0.127   0.80       0.356

  *ABCA1*          Val771Met (G/A)                rs2066718    GG            GA       AA                       3945       550    23     1    0.873   0.122   0.005   0.872   0.123   0.004   0.40       0.066

  *ABCA1*          Arg1587Lys (G/A)               rs2230808    GG            GA       AA                       1673       2154   689    3    0.370   0.477   0.153   0.371   0.476   0.153   0.95       0.391

  *ABCC11*         Arg180Gly (T/C)                rs17822931   TT            TC       CC                       3368       1051   95     5    0.746   0.233   0.021   0.744   0.237   0.019   0.23       0.137

  *ACE*            Insertion/Deletion (I/D)       rs1799752    I/I           I/D      D/D                      1854       2021   634    10   0.411   0.448   0.141   0.404   0.463   0.133   0.029      0.365

  *ADD1*           Trp460Gly (T/G)                rs4961       TT            TG       GG                       1399       2163   956    1    0.310   0.479   0.212   0.301   0.495   0.203   0.026      0.451

  *ADH1B*          His47Arg (A/G)                 rs1229984    AA            AG       GG                       2607       1659   250    3    0.577   0.367   0.055   0.579   0.364   0.057   0.54       0.239

  *ADH1C*          Arg272Gln (C/T)                rs1693482    CC            CT       TT                       3882       591    43     3    0.860   0.131   0.010   0.856   0.139   0.006   0.0005     0.075

  *ADIPOQ*         C-11377G                       rs266729     CC            CG       GG                       2553       1663   301    2    0.565   0.368   0.067   0.561   0.376   0.063   0.18       0.251

  *ADIPOQ*         Gly15Gly (T/G)                 rs2241766    TT            TG       GG                       2314       1789   415    1    0.512   0.396   0.092   0.504   0.412   0.084   0.011      0.290

  *ADIPOQ*         G276T                          rs1501299    GG            GT       TT                       2498       1674   346    1    0.553   0.371   0.077   0.545   0.387   0.069   0.006      0.262

  *ADIPOQ*         IVS-3971A/G                    rs822396     AA            AG       GG                       3984       517    16     2    0.882   0.114   0.004   0.882   0.114   0.004   1.00       0.061

  *ADIPOR1*        G-8503A                        rs6666089    GG            GA       AA                       4234       272    7      6    0.938   0.060   0.002   0.938   0.061   0.001   0.22       0.032

  *ADIPOR1*        C5843T                         rs1342387    CC            CT       TT                       1230       2206   1073   10   0.273   0.489   0.238   0.268   0.499   0.233   0.17       0.483

  *ADIPOR1*        C10224G                        rs7539542    CC            CG       GG                       2788       1505   225    1    0.617   0.333   0.050   0.614   0.339   0.047   0.24       0.216

  *ADRB2*          Gln27Glu (C/G)                 rs1042714    CC            CG       GG                       3943       551    20     5    0.874   0.122   0.004   0.873   0.122   0.004   0.81       0.065

  *ADRB3*          Trp64Arg (T/C)                 rs4994       TT            TC       CC                       2932       1397   182    8    0.650   0.310   0.040   0.648   0.314   0.038   0.34       0.195

  *AGT*            Thr174Met (C/T)                rs4762       CC            CT       TT                       3615       848    52     4    0.801   0.188   0.012   0.800   0.189   0.011   0.75       0.105

  *AGT*            Thr235Met (C/T)                rs699        CC            CT       TT                       2989       1372   157    1    0.662   0.304   0.035   0.662   0.304   0.035   1.00       0.187

  *AGTR1(ATR1)*    A1166C (at 3′UTR)              rs5186       AA            AC       CC                       3777       695    45     2    0.836   0.154   0.010   0.834   0.159   0.008   0.048      0.087

  *ALDH2*          Glu487Lys (G/A)                rs671        GG            GA       AA                       2544       1649   321    5    0.564   0.365   0.071   0.557   0.379   0.064   0.018      0.254

  *APOA1*          Ala61Thr (C/T)                 rs12718465   CC            CT       TT                       4036       463    18     2    0.894   0.103   0.004   0.893   0.104   0.003   0.25       0.055

  *APOA1*          Arg184Pro (G/C)                rs5078       GG            GC       CC                       4512       0      0      7    1.000   0.000   0.000   1.000   0.000   0.000   1.00       0.000

  *APOA5*          T-1131C                        rs662799     TT            TC       CC                       1955       2001   556    7    0.433   0.443   0.123   0.429   0.452   0.119   0.21       0.345

  *APOA5*          Gly185Cys (G553T)              rs2075291    GG            GT       TT                       3920       559    32     8    0.869   0.124   0.007   0.867   0.129   0.005   0.020      0.069

  *APOE*           T-203G                         rs405509     TT            TG       GG                       2213       1847   451    8    0.491   0.409   0.100   0.483   0.424   0.093   0.025      0.305

  *APOE*           Arg158Cys (C/T) (at exon2)     rs7412       CC            CT       TT                       4140       369    9      1    0.916   0.082   0.002   0.916   0.082   0.002   0.72       0.043

  *APOE*           Cys112Arg (T/C) (at exon4)     rs429358     TT            TC       CC                       3669       782    67     1    0.812   0.173   0.015   0.808   0.182   0.010   0.001      0.101

  *ARNTL(BMAL1)*   A/G                            rs7950226    AA            AG       GG                       1638       2102   773    6    0.363   0.466   0.171   0.355   0.482   0.163   0.028      0.404

  *ART4(DOK1)*     Leu208Leu (G/A)                rs3088189    GG            GA       AA                       3595       875    47     2    0.796   0.194   0.010   0.797   0.192   0.012   0.48       0.107

  *ART4(DOK1)*     Asp265Asn (G/A)                rs11276      GG            GA       AA                       3597       872    48     2    0.796   0.193   0.011   0.797   0.191   0.011   0.59       0.107

  *BHMT*           Arg239Gln (G742A)              rs3733890    GG            GA       AA                       2765       1511   241    2    0.612   0.335   0.053   0.607   0.344   0.049   0.069      0.221

  *CBS*            Tyr233Tyr (C699T)              rs234706     CC            CT       TT                       4302       212    2      3    0.953   0.047   0.000   0.953   0.047   0.001   1.00       0.024

  *CD14*           T-260C/T-159C                  rs2569190    TT            TC       CC                       1304       2256   958    1    0.289   0.499   0.212   0.290   0.497   0.213   0.79       0.462

  *CDKAL1*         G/C                            rs7754840    GG            GC       CC                       1581       2195   740    3    0.350   0.486   0.164   0.352   0.483   0.166   0.64       0.407

  *CDKN2A/B*       T/C                            rs10811661   TT            TC       CC                       1379       2205   934    1    0.305   0.488   0.207   0.302   0.495   0.203   0.34       0.451

  *CETP*           A-629C                         rs1800775    AA            AC       CC                       1384       2242   891    2    0.306   0.496   0.197   0.308   0.494   0.198   0.76       0.445

  *CETP*           Ile405Val (A/G)                rs5882       AA            AG       GG                       1236       2116   1166   1    0.274   0.468   0.258   0.258   0.500   0.242   \<0.0001   0.492

  *CETP*           TaqIB (C/T)                    rs708272     CC            CT       TT                       1603       2174   741    1    0.355   0.481   0.164   0.354   0.482   0.164   0.93       0.405

  *CETP*           G/T                            rs3764261    GG            GT       TT                       2707       1512   298    2    0.599   0.335   0.066   0.588   0.358   0.054   \<0.0001   0.233

  *CHRNB2*         G-42A                          rs2072658    GG            GA       AA                       2837       1518   161    3    0.628   0.336   0.036   0.634   0.324   0.042   0.015      0.204

  *CHRNB2*         C/T (at 3′UTR)                 rs2072660    CC            CT       TT                       2601       1641   275    2    0.576   0.363   0.061   0.574   0.367   0.059   0.44       0.243

  *COMT*           Val158Met (G/A)                rs4680       GG            GA       AA                       2006       1983   528    2    0.444   0.439   0.117   0.440   0.446   0.113   0.27       0.336

  *CYP1A1*         Ile462Val (A/G)                rs1048943    AA            AG       GG                       2630       1620   268    1    0.582   0.359   0.059   0.580   0.363   0.057   0.39       0.239

  *CYP1A2*         A734C                          rs762551     AA            AC       CC                       1878       2043   592    6    0.416   0.453   0.131   0.413   0.459   0.128   0.33       0.358

  *CYP11B2*        T-344C                         rs1799998    TT            TC       CC                       2031       1976   507    5    0.450   0.438   0.112   0.447   0.443   0.110   0.42       0.331

  *CYP17A1*        T-34C                          rs743572     TT            TC       CC                       1281       2257   977    4    0.284   0.500   0.216   0.285   0.498   0.217   0.79       0.466

  *ESR1*           IVS1-351A/G (*Xba* I)          rs11155816   AA            AG       GG                       4515       0      0      4    1.000   0.000   0.000   1.000   0.000   0.000   1.00       0.000

  *ESR1*           IVS1-397T/C (*Pvu* II)         rs2234693    TT            TC       CC                       1508       2172   834    5    0.334   0.481   0.185   0.330   0.489   0.181   0.30       0.425

  *ESR2*           Val328Val (G1082A) (*Rsa* I)   rs1256049    GG            GA       AA                       2320       1823   373    3    0.514   0.404   0.083   0.512   0.407   0.081   0.58       0.284

  *FTO*            T/A                            rs9939609    TT            TA       AA                       2881       1454   183    1    0.638   0.322   0.041   0.638   0.322   0.041   1.00       0.201

  *GCK*            G-30A                          rs1799884    GG            GA       AA                       2989       1348   181    1    0.662   0.298   0.040   0.657   0.307   0.036   0.065      0.189

  *GCKR*           A/G                            rs780094     AA            AG       GG                       1379       2221   917    2    0.305   0.492   0.203   0.304   0.495   0.201   0.67       0.449

  *GCKR*           Leu446Pro (T/C)                rs1260326    TT            TC       CC                       1402       2214   902    1    0.310   0.490   0.200   0.308   0.494   0.198   0.61       0.445

  *GNAS1*          T393C                          rs7121       TT            TC       CC                       1466       2233   817    3    0.325   0.494   0.181   0.327   0.490   0.183   0.52       0.428

  *IGF2BP2*        G/T (at intron)                rs4402960    GG            GT       TT                       2215       1866   436    2    0.490   0.413   0.097   0.486   0.422   0.092   0.14       0.303

  *IL-1B*          T-31C                          rs1143627    TT            TC       CC                       1331       2196   990    2    0.295   0.486   0.219   0.289   0.497   0.214   0.14       0.462

  *IL-2*           T-330G                         rs2069762    TT            TG       GG                       2033       1986   494    6    0.450   0.440   0.109   0.450   0.442   0.109   0.79       0.329

  *IL-4*           T-33C                          rs2070874    TT            TC       CC                       1997       1989   531    2    0.442   0.440   0.118   0.439   0.447   0.114   0.30       0.338

  *IL-6*           C-634G                         rs1800796    CC            CG       GG                       2611       1607   298    3    0.578   0.356   0.066   0.572   0.369   0.059   0.019      0.244

  *IL-8*           T-251A                         rs4073       TT            TA       AA                       2077       1952   463    27   0.462   0.435   0.103   0.462   0.435   0.103   0.89       0.320

  *IL-10*          T-819C                         rs1800871    TT            TC       CC                       1942       2009   557    11   0.431   0.446   0.124   0.427   0.453   0.120   0.29       0.346

  *IL-13*          C-1111T                        rs1800925    CC            CT       TT                       3009       1359   147    4    0.666   0.301   0.033   0.667   0.299   0.034   0.69       0.183

  *KCNJ11*         Glu23Lys (C/T)                 rs5219       CC            CT       TT                       1822       2081   615    1    0.403   0.461   0.136   0.401   0.464   0.134   0.59       0.366

  *LCAT/SLC12A4*   Ser232Thr (T/A)                rs4986970    TT            TA       AA                       4516       0      0      3    1.000   0.000   0.000   1.000   0.000   0.000   1.00       0.000

  *LIPC*           T-514C                         rs1800588    TT            TC       CC                       1178       2255   1085   1    0.261   0.499   0.240   0.260   0.500   0.240   0.93       0.490

  *LIPC*           Val95Met (G/A)                 rs6078       GG            GA       AA                       2659       1606   252    2    0.589   0.356   0.056   0.587   0.358   0.055   0.65       0.234

  *MPO*            G-463A                         rs2333227    GG            GA       AA                       3612       852    52     3    0.800   0.189   0.012   0.800   0.189   0.011   0.81       0.106

  *MTHFD1*         Arg134Lys (C401T)              rs1950902    CC            CT       TT                       2773       1517   228    1    0.614   0.336   0.050   0.611   0.341   0.048   0.28       0.218

  *MTHFD1*         Arg653Gln (G1958A)             rs2236225    GG            GA       AA                       2340       1790   384    5    0.518   0.397   0.085   0.514   0.406   0.080   0.12       0.283

  *MTHFR*          Ala222Val (C677T)              rs1801133    CC            CT       TT                       1763       2060   694    2    0.390   0.456   0.154   0.382   0.472   0.146   0.023      0.382

  *MTHFR*          Glu429Ala (A1298C)             rs1801131    AA            AC       CC                       3023       1323   169    4    0.670   0.293   0.037   0.666   0.300   0.034   0.11       0.184

  *MTR*            Asp919Gly (A/G)                rs1805087    AA            AG       GG                       2883       1446   185    5    0.639   0.320   0.041   0.638   0.321   0.040   0.82       0.201

  *MTRR*           Ile22Met (A66G)                rs1801394    AA            AG       GG                       2155       1925   436    3    0.477   0.426   0.097   0.477   0.428   0.096   0.83       0.310

  *NOS3*           T-786C                         rs2070744    TT            TC       CC                       3602       863    48     6    0.798   0.191   0.011   0.799   0.190   0.011   0.70       0.106

  *PPARD*          T-842C (at exon3)              rs2267668    TT            TC       CC                       2922       1421   172    4    0.647   0.315   0.038   0.647   0.315   0.038   1.00       0.195

  *PPARD*          T-48444C (at exon3)            rs6902123    TT            TC       CC                       4343       173    2      1    0.961   0.038   0.000   0.961   0.038   0.000   0.69       0.020

  *PPARD*          Asn163Asn (A65G) (at exon7)    rs2076167    AA            AG       GG                       2780       1530   204    5    0.616   0.339   0.045   0.617   0.337   0.046   0.76       0.215

  *PPARG*          Pro12Ala (C/G)                 rs1801282    CC            CG       GG                       4236       274    5      4    0.938   0.061   0.001   0.938   0.061   0.001   0.80       0.031

  *PPARG*          His477His (C161T)              rs3856806    CC            CT       TT                       3231       1198   86     4    0.716   0.265   0.019   0.720   0.257   0.023   0.043      0.152

  *PPARGC1A*       Thr394Thr (C/T)                rs2970847    CC            CT       TT                       2755       1539   221    4    0.610   0.341   0.049   0.609   0.343   0.048   0.76       0.219

  *PPARGC1A*       Gly482Ser (G/A)                rs8192678    GG            GA       AA                       1317       2247   952    3    0.292   0.498   0.211   0.292   0.497   0.211   0.93       0.460

  *PRKAA2*         IVS4+961T/C                    rs1418442    TT            TC       CC                       2677       1581   251    10   0.594   0.351   0.056   0.591   0.355   0.053   0.38       0.231

  *PRKAA2*         IVS7+81T/C                     rs932447     TT            TC       CC                       2679       1585   252    3    0.593   0.351   0.056   0.591   0.356   0.053   0.38       0.231

  *PRKAA2*         A/T (at 3′UTR)                 rs1342382    AA            AT       TT                       2739       1556   218    6    0.607   0.345   0.048   0.607   0.344   0.049   0.90       0.221

  *PTGS2(COX2)*    G-765C                         rs20417      GG            GC       CC                       4260       247    6      6    0.944   0.055   0.001   0.943   0.056   0.001   0.27       0.029

  *PTGS2(COX2)*    C-163G                         rs5270       CC            CG       GG                       4379       136    3      1    0.969   0.030   0.001   0.969   0.031   0.000   0.10       0.016

  *PTPN11*         G33861A                        rs2301756    GG            GA       AA                       2926       1418   174    1    0.648   0.314   0.039   0.647   0.314   0.038   0.89       0.195

  *RETN*           C-420G                         rs1862513    CC            CG       GG                       1956       1977   585    1    0.433   0.438   0.129   0.425   0.454   0.121   0.015      0.348

  *SCARB1*         Val135Ile (G/A)                rs5891       GG            GA       AA                       4518       0      0      1    1.000   0.000   0.000   1.000   0.000   0.000   1.00       0.000

  *SCARB1*         Ala350Ala (C1119T)             rs5888       CC            CT       TT                       2678       1619   221    1    0.593   0.358   0.049   0.596   0.352   0.052   0.25       0.228

  *SCARB1*         G/A (at intron)                rs3782287    GG            GA       AA                       2676       1574   268    1    0.592   0.348   0.059   0.588   0.358   0.055   0.074      0.234

  *SERPINC1*       C/G                            rs677        CC            CG       GG                       2762       1527   227    3    0.612   0.338   0.050   0.609   0.342   0.048   0.41       0.219

  *SHMT1*          Leu435Phe (C1420T)             rs1979277    CC            CT       TT                       3755       722    41     1    0.831   0.160   0.009   0.830   0.162   0.008   0.36       0.089

  *SLC19A(RFC1)*   His27Arg (A80G)                rs1051266    AA            AG       GG                       1536       2187   793    3    0.340   0.484   0.176   0.339   0.486   0.175   0.76       0.418

  *SLC30A8*        Arg325Trp (C/T)                rs13266634   CC            CT       TT                       1543       1992   976    8    0.342   0.442   0.216   0.317   0.492   0.191   \<0.0001   0.437

  *SRD5A2*         Leu89Val (C/G)                 rs523349     CC            CG       GG                       1334       2286   896    3    0.295   0.506   0.198   0.301   0.495   0.204   0.15       0.452

  *TAS2R38*        Pro49Ala (C/G)                 rs713598     CC            CG       GG                       1399       2219   898    3    0.310   0.491   0.199   0.309   0.494   0.198   0.74       0.445

  *TAS2R38*        Ala262Val (C/T)                rs1726866    CC            CT       TT                       1401       2218   899    1    0.310   0.491   0.199   0.309   0.494   0.198   0.70       0.444

  *TAS2R38*        Val296Ile (C/T)                rs10246939   CC            CT       TT                       1401       2218   898    2    0.310   0.491   0.199   0.309   0.494   0.197   0.72       0.444

  *TCF7L2*         C/T (at intron)                rs7903146    CC            CT       TT                       4174       333    11     1    0.924   0.074   0.002   0.923   0.075   0.002   0.11       0.039

  *TNF-A*          T-1031C                        rs1799964    TT            TC       CC                       3147       1244   127    1    0.697   0.275   0.028   0.696   0.277   0.027   0.75       0.166

  *TNF-A*          C-857T                         rs1799724    CC            CT       TT                       2990       1365   162    2    0.662   0.302   0.036   0.661   0.304   0.035   0.70       0.187

  *USF1*           C7131T                         rs3737787    CC            CT       TT                       2793       1506   218    2    0.618   0.333   0.048   0.616   0.338   0.046   0.43       0.215

  *VDR*            Met1Thr (*Fok* I) (C/T)        rs2228570    CC            CT       TT                       1768       2105   643    3    0.391   0.466   0.142   0.390   0.469   0.141   0.68       0.375
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: HWE, Hardy--Weinberg equilibrium; MAF, minor allele frequency; SNP, single nucleotide polymorphism.

^a^AA, Aa, aa, and XX indicate homozygotes of major alleles, heterozygotes, homozygotes of minor alleles, and samples for which the genotype could not be determined, respectively.

^b^Based on the Hardy--Weinberg equilibrium.

The *P* value for departures from the Hardy--Weinberg equilibrium was less than 0.05 for 19 polymorphisms. However, the only genotypes for which the difference between the observed and expected frequencies exceeded 3% were the *CETP* Ile405Val (A/G) heterozygote and the *SLC30A8* Arg325Trp (C/T) heterozygote. As shown in Table [5](#tbl05){ref-type="table"}, some polymorphisms demonstrated a considerable difference in MAF among the participating cohorts; for 32 of the 108 polymorphisms, including *ABCC11* Arg180Gly (T/C), there was a highly significant difference in MAF among study areas (*P* \< 0.001).

###### Minor allele frequencies of 107 selected genetic polymorphisms (106 SNPs and 1 insertion/deletion polymorphism) by study area

  Gene             Polymorphism                   rs number    Minor allele frequency by study area   *P*^a^                                                                           
  ---------------- ------------------------------ ------------ -------------------------------------- -------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ----------
  *ABCA1*          C-565T                         rs2422493    0.402                                  0.371    0.429   0.406   0.426   0.401   0.394   0.468   0.404   0.405   0.355   0.005
  *ABCA1*          G-191C                         rs1800976    0.402                                  0.370    0.429   0.406   0.425   0.403   0.403   0.468   0.408   0.405   0.356   0.006
  *ABCA1*          G-17C                          rs2740483    0.301                                  0.363    0.296   0.300   0.271   0.294   0.300   0.247   0.313   0.313   0.271   0.0002
  *ABCA1*          Val825Ile (G/A)                rs2066715    0.356                                  0.354    0.358   0.331   0.354   0.350   0.347   0.353   0.360   0.358   0.389   0.51
  *ABCA1*          Val771Met (G/A)                rs2066718    0.066                                  0.067    0.060   0.067   0.059   0.061   0.034   0.047   0.073   0.068   0.088   0.041
  *ABCA1*          Arg1587Lys (G/A)               rs2230808    0.391                                  0.393    0.391   0.384   0.392   0.394   0.347   0.326   0.369   0.388   0.441   0.027
  *ACE*            Insertion/Deletion (I/D)       rs1799752    0.365                                  0.373    0.369   0.346   0.363   0.365   0.313   0.353   0.357   0.341   0.425   0.003
  *ADD1*           Trp460Gly (T/G)                rs4961       0.451                                  0.454    0.436   0.424   0.455   0.430   0.463   0.463   0.429   0.464   0.509   0.006
  *ADH1B*          His47Arg (A/G)                 rs1229984    0.239                                  0.220    0.232   0.200   0.247   0.220   0.250   0.184   0.266   0.223   0.318   \<0.0001
  *ADH1C*          Arg272Gln (C/T)                rs1693482    0.075                                  0.053    0.068   0.054   0.178   0.056   0.053   0.058   0.065   0.053   0.072   \<0.0001
  *ADIPOQ*         C-11377G                       rs266729     0.251                                  0.245    0.239   0.254   0.238   0.252   0.300   0.279   0.257   0.250   0.255   0.60
  *ADIPOQ*         Gly15Gly (T/G)                 rs2241766    0.290                                  0.285    0.304   0.285   0.309   0.301   0.316   0.295   0.287   0.284   0.251   0.18
  *ADIPOQ*         G276T                          rs1501299    0.262                                  0.290    0.284   0.282   0.147   0.266   0.263   0.289   0.286   0.308   0.236   \<0.0001
  *ADIPOQ*         IVS-3971A/G                    rs822396     0.061                                  0.053    0.049   0.069   0.057   0.079   0.050   0.047   0.073   0.057   0.056   0.063
  *ADIPOR1*        G-8503A                        rs6666089    0.032                                  0.029    0.040   0.034   0.028   0.027   0.044   0.026   0.029   0.024   0.040   0.29
  *ADIPOR1*        C5843T                         rs1342387    0.483                                  0.484    0.473   0.476   0.481   0.480   0.478   0.426   0.495   0.483   0.504   0.78
  *ADIPOR1*        C10224G                        rs7539542    0.216                                  0.226    0.230   0.201   0.202   0.223   0.219   0.263   0.233   0.215   0.194   0.21
  *ADRB2*          Gln27Glu (C/G)                 rs1042714    0.065                                  0.073    0.051   0.061   0.066   0.093   0.081   0.079   0.072   0.063   0.039   0.0001
  *ADRB3*          Trp64Arg (T/C)                 rs4994       0.195                                  0.184    0.173   0.195   0.184   0.195   0.147   0.168   0.193   0.218   0.240   0.001
  *AGT*            Thr174Met (C/T)                rs4762       0.105                                  0.104    0.106   0.101   0.106   0.092   0.094   0.095   0.123   0.105   0.115   0.68
  *AGT*            Thr235Met (C/T)                rs699        0.187                                  0.181    0.183   0.208   0.189   0.195   0.219   0.211   0.173   0.178   0.170   0.31
  *AGTR1(ATR1)*    A1166C (at 3′UTR)              rs5186       0.087                                  0.089    0.093   0.083   0.088   0.076   0.081   0.089   0.080   0.082   0.104   0.61
  *ALDH2*          Glu487Lys (G/A)                rs671        0.254                                  0.232    0.274   0.316   0.298   0.254   0.226   0.300   0.269   0.267   0.112   \<0.0001
  *APOA1*          Ala61Thr (C/T)                 rs12718465   0.055                                  0.051    0.049   0.056   0.061   0.055   0.088   0.016   0.046   0.043   0.079   0.0005
  *APOA1*          Arg184Pro (G/C)                rs5078       0.000                                  0.000    0.000   0.000   0.000   0.000   0.000   0.000   0.000   0.000   0.000    
  *APOA5*          T-1131C                        rs662799     0.345                                  0.355    0.336   0.322   0.337   0.326   0.338   0.342   0.342   0.337   0.412   0.002
  *APOA5*          Gly185Cys (G553T)              rs2075291    0.069                                  0.084    0.062   0.057   0.073   0.068   0.063   0.074   0.064   0.079   0.065   0.36
  *APOE*           T-203G                         rs405509     0.305                                  0.289    0.297   0.294   0.302   0.256   0.306   0.295   0.318   0.308   0.383   \<0.0001
  *APOE*           Arg158Cys (C/T) (at exon2)     rs7412       0.043                                  0.045    0.048   0.048   0.035   0.042   0.050   0.042   0.044   0.048   0.030   0.49
  *APOE*           Cys112Arg (T/C) (at exon4)     rs429358     0.101                                  0.105    0.105   0.101   0.123   0.101   0.078   0.068   0.109   0.102   0.075   0.026
  *ARNTL(BMAL1)*   A/G                            rs7950226    0.404                                  0.424    0.405   0.420   0.395   0.402   0.391   0.347   0.427   0.431   0.344   0.002
  *ART4(DOK1)*     Leu208Leu (G/A)                rs3088189    0.107                                  0.114    0.114   0.130   0.084   0.113   0.078   0.068   0.105   0.108   0.109   0.022
  *ART4(DOK1)*     Asp265Asn (G/A)                rs11276      0.107                                  0.114    0.113   0.130   0.084   0.113   0.078   0.068   0.105   0.108   0.109   0.023
  *BHMT*           Arg239Gln (G742A)              rs3733890    0.221                                  0.235    0.236   0.241   0.229   0.203   0.209   0.226   0.243   0.217   0.164   0.0005
  *CBS*            Tyr233Tyr (C699T)              rs234706     0.024                                  0.027    0.033   0.026   0.020   0.021   0.028   0.011   0.034   0.017   0.017   0.073
  *CD14*           T-260C/T-159C                  rs2569190    0.462                                  0.460    0.467   0.467   0.439   0.499   0.428   0.395   0.468   0.448   0.471   0.088
  *CDKAL1*         G/C                            rs7754840    0.407                                  0.428    0.390   0.430   0.392   0.411   0.363   0.374   0.424   0.435   0.367   0.009
  *CDKN2A/B*       T/C                            rs10811661   0.451                                  0.465    0.450   0.466   0.446   0.470   0.453   0.411   0.441   0.452   0.419   0.42
  *CETP*           A-629C                         rs1800775    0.445                                  0.445    0.463   0.442   0.436   0.441   0.469   0.405   0.462   0.422   0.458   0.52
  *CETP*           Ile405Val (A/G)                rs5882       0.492                                  0.537    0.376   0.452   0.523   0.498   0.509   0.458   0.495   0.556   0.506   \<0.0001
  *CETP*           TaqIB (C/T)                    rs708272     0.405                                  0.404    0.401   0.419   0.419   0.384   0.375   0.363   0.378   0.443   0.398   0.067
  *CETP*           G/T                            rs3764261    0.233                                  0.183    0.340   0.295   0.203   0.188   0.209   0.158   0.204   0.223   0.240   \<0.0001
  *CHRNB2*         G-42A                          rs2072658    0.204                                  0.236    0.214   0.185   0.215   0.222   0.203   0.253   0.202   0.203   0.140   \<0.0001
  *CHRNB2*         C/T (at 3′UTR)                 rs2072660    0.243                                  0.258    0.225   0.264   0.224   0.241   0.216   0.237   0.214   0.233   0.292   0.001
  *COMT*           Val158Met (G/A)                rs4680       0.336                                  0.310    0.328   0.336   0.323   0.359   0.303   0.295   0.336   0.315   0.406   \<0.0001
  *CYP1A1*         Ile462Val (A/G)                rs1048943    0.239                                  0.222    0.235   0.256   0.222   0.244   0.250   0.268   0.222   0.225   0.274   0.069
  *CYP1A2*         A734C                          rs762551     0.358                                  0.336    0.349   0.356   0.344   0.367   0.352   0.384   0.351   0.363   0.391   0.38
  *CYP11B2*        T-344C                         rs1799998    0.331                                  0.334    0.318   0.339   0.289   0.294   0.346   0.284   0.329   0.325   0.434   \<0.0001
  *CYP17A1*        T-34C                          rs743572     0.466                                  0.453    0.460   0.449   0.485   0.492   0.500   0.353   0.467   0.452   0.482   0.018
  *ESR1*           IVS1-351A/G (*Xba* I)          rs11155816   0.000                                  0.000    0.000   0.000   0.000   0.000   0.000   0.000   0.000   0.000   0.000    
  *ESR1*           IVS1-397T/C (*Pvu* II)         rs2234693    0.425                                  0.436    0.422   0.422   0.416   0.452   0.334   0.421   0.430   0.438   0.415   0.062
  *ESR2*           Val328Val (G1082A) (*Rsa* I)   rs1256049    0.284                                  0.268    0.281   0.297   0.272   0.308   0.272   0.284   0.314   0.293   0.250   0.054
  *FTO*            T/A                            rs9939609    0.201                                  0.172    0.195   0.220   0.190   0.188   0.169   0.158   0.206   0.186   0.277   \<0.0001
  *GCK*            G-30A                          rs1799884    0.189                                  0.193    0.179   0.183   0.186   0.182   0.138   0.147   0.304   0.173   0.159   \<0.0001
  *GCKR*           A/G                            rs780094     0.449                                  0.428    0.436   0.440   0.439   0.425   0.350   0.453   0.450   0.445   0.562   \<0.0001
  *GCKR*           Leu446Pro (T/C)                rs1260326    0.445                                  0.430    0.434   0.439   0.438   0.416   0.353   0.421   0.447   0.432   0.559   \<0.0001
  *GNAS1*          T393C                          rs7121       0.428                                  0.448    0.427   0.408   0.463   0.422   0.469   0.342   0.454   0.418   0.391   0.002
  *IGF2BP2*        G/T (at intron)                rs4402960    0.303                                  0.328    0.306   0.292   0.298   0.296   0.309   0.268   0.300   0.304   0.306   0.81
  *IL-1B*          T-31C                          rs1143627    0.462                                  0.444    0.463   0.477   0.439   0.454   0.491   0.484   0.477   0.462   0.475   0.52
  *IL-2*           T-330G                         rs2069762    0.329                                  0.330    0.336   0.316   0.311   0.323   0.309   0.305   0.350   0.321   0.365   0.21
  *IL-4*           T-33C                          rs2070874    0.338                                  0.317    0.337   0.315   0.333   0.291   0.313   0.284   0.336   0.337   0.457   \<0.0001
  *IL-6*           C-634G                         rs1800796    0.244                                  0.247    0.206   0.250   0.234   0.226   0.225   0.232   0.223   0.240   0.338   \<0.0001
  *IL-8*           T-251A                         rs4073       0.320                                  0.334    0.321   0.318   0.320   0.304   0.331   0.266   0.339   0.329   0.306   0.56
  *IL-10*          T-819C                         rs1800871    0.346                                  0.329    0.346   0.320   0.340   0.313   0.356   0.268   0.354   0.359   0.425   \<0.0001
  *IL-13*          C-1111T                        rs1800925    0.183                                  0.182    0.178   0.197   0.185   0.178   0.213   0.158   0.172   0.190   0.176   0.73
  *KCNJ11*         Glu23Lys (C/T)                 rs5219       0.366                                  0.386    0.364   0.382   0.343   0.374   0.363   0.316   0.361   0.366   0.368   0.52
  *LCAT/SLC12A4*   Ser232Thr (T/A)                rs4986970    0.000                                  0.000    0.000   0.000   0.000   0.000   0.000   0.000   0.000   0.000   0.000    
  *LIPC*           T-514C                         rs1800588    0.490                                  0.522    0.478   0.496   0.484   0.497   0.522   0.484   0.502   0.503   0.429   0.006
  *LIPC*           Val95Met (G/A)                 rs6078       0.234                                  0.232    0.229   0.221   0.269   0.259   0.247   0.237   0.208   0.253   0.182   \<0.0001
  *MPO*            G-463A                         rs2333227    0.106                                  0.107    0.105   0.107   0.102   0.113   0.100   0.100   0.106   0.093   0.119   0.84
  *MTHFD1*         Arg134Lys (C401T)              rs1950902    0.218                                  0.214    0.216   0.218   0.212   0.229   0.184   0.195   0.217   0.239   0.215   0.66
  *MTHFD1*         Arg653Gln (G1958A)             rs2236225    0.283                                  0.271    0.273   0.269   0.265   0.280   0.284   0.279   0.278   0.301   0.331   0.036
  *MTHFR*          Ala222Val (C677T)              rs1801133    0.382                                  0.387    0.402   0.388   0.411   0.393   0.375   0.442   0.410   0.364   0.288   \<0.0001
  *MTHFR*          Glu429Ala (A1298C)             rs1801131    0.184                                  0.195    0.189   0.202   0.193   0.193   0.225   0.191   0.147   0.222   0.105   \<0.0001
  *MTR*            Asp919Gly (A/G)                rs1805087    0.201                                  0.188    0.210   0.186   0.183   0.179   0.184   0.232   0.193   0.176   0.299   \<0.0001
  *MTRR*           Ile22Met (A66G)                rs1801394    0.310                                  0.292    0.314   0.298   0.315   0.296   0.306   0.337   0.318   0.297   0.346   0.24
  *NOS3*           T-786C                         rs2070744    0.106                                  0.111    0.125   0.117   0.112   0.098   0.119   0.122   0.109   0.102   0.068   0.004
  *PPARD*          T-842C (at exon3)              rs2267668    0.195                                  0.175    0.199   0.201   0.183   0.205   0.213   0.221   0.192   0.190   0.210   0.55
  *PPARD*          T-48444C (at exon3)            rs6902123    0.020                                  0.015    0.020   0.030   0.025   0.017   0.019   0.016   0.019   0.019   0.012   0.15
  *PPARD*          Asn163Asn (A65G) (at exon7)    rs2076167    0.215                                  0.190    0.212   0.231   0.206   0.221   0.225   0.234   0.209   0.205   0.236   0.30
  *PPARG*          Pro12Ala (C/G)                 rs1801282    0.031                                  0.031    0.027   0.028   0.037   0.047   0.022   0.011   0.029   0.032   0.025   0.064
  *PPARG*          His477His (C161T)              rs3856806    0.152                                  0.153    0.159   0.143   0.149   0.167   0.159   0.147   0.177   0.166   0.099   0.0002
  *PPARGC1A*       Thr394Thr (C/T)                rs2970847    0.219                                  0.229    0.223   0.237   0.219   0.222   0.209   0.237   0.208   0.243   0.168   0.005
  *PPARGC1A*       Gly482Ser (G/A)                rs8192678    0.460                                  0.472    0.447   0.444   0.431   0.448   0.463   0.442   0.471   0.438   0.538   \<0.0001
  *PRKAA2*         IVS4+961T/C                    rs1418442    0.231                                  0.216    0.228   0.232   0.206   0.217   0.184   0.237   0.205   0.237   0.318   \<0.0001
  *PRKAA2*         IVS7+81T/C                     rs932447     0.231                                  0.216    0.228   0.232   0.207   0.218   0.184   0.237   0.205   0.239   0.318   \<0.0001
  *PRKAA2*         A/T (at 3′UTR)                 rs1342382    0.221                                  0.238    0.220   0.200   0.250   0.225   0.204   0.211   0.233   0.197   0.212   0.072
  *PTGS2(COX2)*    G-765C                         rs20417      0.029                                  0.028    0.033   0.031   0.033   0.027   0.025   0.053   0.026   0.030   0.017   0.22
  *PTGS2(COX2)*    C-163G                         rs5270       0.016                                  0.017    0.023   0.017   0.020   0.015   0.009   0.011   0.009   0.011   0.016   0.32
  *PTPN11*         G33861A                        rs2301756    0.195                                  0.194    0.199   0.172   0.167   0.185   0.184   0.205   0.173   0.159   0.320   \<0.0001
  *RETN*           C-420G                         rs1862513    0.348                                  0.351    0.328   0.330   0.343   0.330   0.334   0.316   0.340   0.366   0.411   0.002
  *SCARB1*         Val135Ile (G/A)                rs5891       0.000                                  0.000    0.000   0.000   0.000   0.000   0.000   0.000   0.000   0.000   0.000    
  *SCARB1*         Ala350Ala (C1119T)             rs5888       0.228                                  0.240    0.212   0.226   0.228   0.225   0.253   0.205   0.240   0.240   0.213   0.59
  *SCARB1*         G/A (at intron)                rs3782287    0.234                                  0.225    0.223   0.243   0.227   0.249   0.297   0.189   0.207   0.219   0.263   0.008
  *SERPINC1*       C/G                            rs677        0.219                                  0.220    0.197   0.209   0.238   0.223   0.238   0.211   0.220   0.227   0.217   0.58
  *SHMT1*          Leu435Phe (C1420T)             rs1979277    0.089                                  0.072    0.089   0.071   0.093   0.092   0.084   0.095   0.084   0.091   0.117   0.026
  *SLC19A(RFC1)*   His27Arg (A80G)                rs1051266    0.418                                  0.415    0.435   0.412   0.426   0.423   0.397   0.395   0.430   0.454   0.352   0.001
  *SLC30A8*        Arg325Trp (C/T)                rs13266634   0.437                                  0.439    0.449   0.443   0.438   0.418   0.472   0.453   0.434   0.451   0.411   0.53
  *SRD5A2*         Leu89Val (C/G)                 rs523349     0.452                                  0.437    0.468   0.430   0.458   0.458   0.391   0.399   0.449   0.471   0.464   0.13
  *TAS2R38*        Pro49Ala (C/G)                 rs713598     0.445                                  0.448    0.439   0.419   0.427   0.454   0.434   0.479   0.445   0.435   0.491   0.080
  *TAS2R38*        Ala262Val (C/T)                rs1726866    0.444                                  0.449    0.438   0.419   0.427   0.454   0.434   0.479   0.444   0.435   0.491   0.078
  *TAS2R38*        Val296Ile (C/T)                rs10246939   0.444                                  0.448    0.438   0.419   0.427   0.454   0.434   0.479   0.444   0.435   0.491   0.079
  *TCF7L2*         C/T (at intron)                rs7903146    0.039                                  0.051    0.039   0.042   0.043   0.037   0.034   0.042   0.025   0.034   0.043   0.27
  *TNF-A*          T-1031C                        rs1799964    0.166                                  0.175    0.148   0.165   0.157   0.153   0.153   0.237   0.151   0.180   0.188   0.024
  *TNF-A*          C-857T                         rs1799724    0.187                                  0.172    0.171   0.173   0.166   0.161   0.194   0.184   0.203   0.199   0.255   \<0.0001
  *USF1*           C7131T                         rs3737787    0.215                                  0.229    0.223   0.220   0.234   0.217   0.263   0.216   0.196   0.204   0.178   0.020
  *VDR*            Met1Thr (*Fok* I) (C/T)        rs2228570    0.375                                  0.344    0.393   0.368   0.380   0.381   0.391   0.437   0.402   0.377   0.343   0.048

Abbreviations: ACC, Aichi Cancer Center; SNP, single nucleotide polymorphism.

^a^*P* for difference among study areas.

The [Figure](#fig01){ref-type="fig"} shows a comparison of the allele frequencies in our study population and the HapMap-JPT data set. Among 88 polymorphisms, only 5 (*ABCA1* rs2230808, *COMT* rs4680, *IL-6* rs1800796, *NOS3* rs2070744, and *VDR* rs2228570) showed a difference in allele frequencies of more than 0.1 between the 2 populations.

![Scatter plot of allele frequencies for 88 polymorphisms in the data set from the Japan Multi-institutional Collaborative Cohort (J-MICC) Study and the HapMap-JPT data set registered at the US National Library of Medicine (<http://www.ncbi.nlm.nih.gov/snp>). Points on the identity (dotted) line represent allele frequencies that are identical in the 2 populations.](je-21-223-g001){#fig01}

DISCUSSION
==========

The present report describes the profiles of participants in a cross-sectional study within the J-MICC Study data set and the allele frequencies of 108 polymorphisms, with potential relevance to lifestyle and clinical factors, in their genomes. The allele frequencies for most polymorphisms in our study population were comparable to those in the HapMap-JPT data set.

It has been suggested that polymorphisms for *APOA1* 184Pro (C), *ESR1* IVS1-351G, *LCAT/SLC12A4* 232Thr (A), and *SCARB1* 135Ile (A) do not exist in the Japanese population (<http://www.ncbi.nlm.nih.gov/snp> and personal communication); however, we included them in the present study to test this notion in a large sample (\>4000 people). Our results confirmed that these minor alleles were indeed absent among Japanese.

Of the remaining 104 polymorphisms, 19 showed departures from the Hardy--Weinberg equilibrium with *P* values \<0.05. In most cases, however, the absolute differences between the actual and expected frequencies were minimal. Thus, these apparently small *P* values could be accounted for by the large sample size and the multiple tests used in our study, and any errors in genotyping seemed unlikely to have resulted in substantial misclassification.

Although genotype data for only 45 people, at most, are available in the HapMap-JPT data set, the allele frequencies in the HapMap-JPT population and our study population were remarkably similar for most of the polymorphisms examined ([Figure](#fig01){ref-type="fig"}). For 45 individuals, the 95% confidence intervals were 0.047 to 0.181, 0.208 to 0.406, and 0.393 to 0.607 for MAF values of 0.1, 0.3, and 0.5, respectively, based on a binomial distribution.

A major strength of the current study was that it provided a comprehensive collection of data on lifestyle and clinical factors. Because it is not easy to gain access to data on genotype distributions in a large Japanese population, our data might also be useful as a reference tool. However, because the participants in this study were recruited from various sources throughout Japan, associations of genotypes with lifestyle and clinical factors might vary between populations. There might also have been differences between institutions in terms of the measurement methods used in the clinical examinations, because we could not directly control the quality of the health examinations. These differences must be taken into consideration when analyzing and interpreting the data. In addition, some polymorphisms showed a substantial difference in MAF among the participating cohorts (Table [5](#tbl05){ref-type="table"}). Yamaguchi-Kabata et al suggested that individuals from the Ryukyu Islands, including the Amami Islands, had genetic characteristics that differed considerably from those of individuals from the main islands of Japan,^[@r22]^ which was consistent with our present results. Genetic variations among study areas should be taken into account in the data analysis. Furthermore, the generalizability of the study findings should be considered because the response rates were low in some areas. In most cases, however, the underlying biological mechanisms are unlikely to differ between the respondents and members of the general population. The low response rate might have been due to the recruitment methods (mailing invitation letters or distributing leaflets to the general populations of 3 areas) or the strict procedures used to obtain informed consent.

In conclusion, this comprehensive data collection on lifestyle and clinical factors will be useful in elucidating gene--environment interactions and could provide an informative reference tool, particularly because free access to genotype data for a large Japanese population is not readily available.
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